Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
How has Daichi Fujimoto's publication output changed over time?
ScholarIQpublication output · 2016–2022
Output grew0% over the shown period — from 2 works in 2016 to 2 in 2022.
2
2
2
2
1
2
201620172018201920212022
What are the most-cited papers on Daichi Fujimoto?
ScholarIQmost cited works
Early Immune-Related Adverse Events and Association with Outcome in Advanced Non–Small Cell Lung Cancer Patients Treated with Nivolumab: A Prospective Cohort Study
Shunsuke Teraoka, Daichi Fujimoto, Takeshi Morimoto, Hayato Kawachi, Munehiro Ito, Yuki Sato, Kazuma Nagata, Atsushi Nakagawa, Kojiro Otsuka, Keiichiro Uehara, Yukihiro Imai, Kaori Shintani‐Ishida, Junya Fukuoka, Keisuke Tomii
Journal of Thoracic Oncology. 2017379 CitationsOPEN ACCESS
Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With <i>EGFR</i> T790M–Mutated Non–Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor
Hiroaki Akamatsu, Yukihiro Toi, Hidetoshi Hayashi, Daichi Fujimoto, Motoko Tachihara, Naoki Furuya, Sakiko Otani, Junichi Shimizu, Nobuyuki Katakami, Koichi Azuma, Naoko Miura, Kazumi Nishino, Satoshi Hara, Shunsuke Teraoka, Satoshi Morita, Kazuhiko Nakagawa, Nobuyuki Yamamoto
JAMA Oncology. 2021187 CitationsOPEN ACCESS
“Interchangeability” of PD-L1 immunohistochemistry assays: a meta-analysis of diagnostic accuracy
Emina Torlakovic, Hyun J. Lim, Julien Adam, Penny J. Barnes, Gilbert Bigras, Anthony W.H. Chan, Carol C. Cheung, Jin-Haeng Chung, Christian Couture, Pierre Fiset, Daichi Fujimoto, Gang Han, Fred R. Hirsch, Marius Ilié, Diana N. Ionescu, Chao Li, Enrico Munari, Katsuhiro Okuda, M. Ratcliffe, David L. Rimm, Catherine Ross, Rasmus Røge, Andreas H. Scheel, Ross A. Soo, Paul E. Swanson, Maria Tretiakova, Ka‐Fai To, Gilad W. Vainer, Hangjun Wang, Zhaolin Xu, Dirk Zielinski, Ming‐Sound Tsao
S33606366. 2019178 CitationsOPEN ACCESS
Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L
Yoshiko Urata, Nobuyuki Katakami, Satoshi Morita, Reiko Kaji, Hiroshige Yoshioka, Takashi Seto, Miyako Satouchi, Yasuo Iwamoto, Masashi Kanehara, Daichi Fujimoto, Norihiko Ikeda, Haruyasu Murakami, Haruko Daga, Tetsuya Oguri, Isao Goto, Fumio Imamura, Shunichi Sugawara, Hideo Saka, Naoyuki Nogami, Shunichi Negoro, Kazuhiko Nakagawa, Yoichi Nakanishi
Journal of Clinical Oncology. 2016160 Citations
Randomized Phase 2 Study of Osimertinib Plus Bevacizumab Versus Osimertinib for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations: WJOG9717L Study
Hirotsugu Kenmotsu, Kazushige Wakuda, Keita Mori, Terufumi Kato, Shunichi Sugawara, Keisuke Kirita, Yasuto Yoneshima, Koichi Azuma, Kazumi Nishino, Shunsuke Teraoka, Takehito Shukuya, Ken Masuda, Hidetoshi Hayashi, Ryo Toyozawa, Satoru Miura, Daichi Fujimoto, Kazuhiko Nakagawa, Nobuyuki Yamamoto, Toshiaki Takahashi
Journal of Thoracic Oncology. 2022160 CitationsOPEN ACCESS
Related on ScholarIQ
Hyogo University
Institution
Early Immune-Related Adverse Events and Association with Outcome in Advanced Non–Small Cell Lung Cancer Patients Treated with Nivolumab: A Prospective Cohort Study
Paper
Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With <i>EGFR</i> T790M–Mutated Non–Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor
Paper
“Interchangeability” of PD-L1 immunohistochemistry assays: a meta-analysis of diagnostic accuracy
Paper
Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L
Paper
Randomized Phase 2 Study of Osimertinib Plus Bevacizumab Versus Osimertinib for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations: WJOG9717L Study
Paper